We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ciphergen Paper Recognized as ScienceDirect TOP25 Hottest Articles by Elsevier
News

Ciphergen Paper Recognized as ScienceDirect TOP25 Hottest Articles by Elsevier

Ciphergen Paper Recognized as ScienceDirect TOP25 Hottest Articles by Elsevier
News

Ciphergen Paper Recognized as ScienceDirect TOP25 Hottest Articles by Elsevier

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ciphergen Paper Recognized as ScienceDirect TOP25 Hottest Articles by Elsevier "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ciphergen Biosystems, Inc. has announced the receipt of a diploma from Elsevier publishers recognizing a recent paper as one of the top five papers downloaded from the website of the journal Clin Chim Acta.

The paper titled, "Proteome Analysis in the Clinical Chemistry Laboratory; Myth or Reality?" provides an overview of available technologies for proteomic analysis, particularly for the discovery of disease biomarkers.

The paper describes the challenges of the dynamic range of the proteome, and demonstrates how Ciphergen's Equalizer Bead technology can help address this challenge.

The paper was authored by Dr. Pier Giorgio Righetti at the University of Verona and Dr. Egisto Boschetti at Ciphergen, and their colleagues.

"The popularity of this paper demonstrates the urgent need for new technologies that can aid scientists and clinicians in the discovery of new protein markers," said Gail S. Page, President and CEO.

"The novel technologies, such as Equalizer Beads, that we are developing will enable our collaborators and us to achieve this goal and develop novel high-value diagnostic tests."

Advertisement